These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 21049556)

  • 21. HIV-1 tropism and liver fibrosis in HIV-HCV co-infected patients.
    Abravanel F; Raymond S; Pambrun E; Winnock M; Bonnard P; Sogni P; Trimoulet P; Dabis F; Salmon-Ceron D; Izopet J;
    PLoS One; 2012; 7(11):e50289. PubMed ID: 23226258
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Liver fibrosis in patients with chronic hepatitis C and persistently normal liver enzymes: influence of HIV infection.
    Martin-Carbonero L; de Ledinghen V; Moreno A; Maida I; Foucher J; Barreiro P; Romero M; Satta G; Garcia-Samaniego J; Gonzalez-Lahoz J; Soriano V
    J Viral Hepat; 2009 Nov; 16(11):790-5. PubMed ID: 19413693
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diagnostic accuracy of APRI, FIB-4 and Forns for the detection of liver cirrhosis in HIV/HCV-coinfected patients.
    Merli M; Galli L; Castagna A; Salpietro S; Gianotti N; Messina E; Poli A; Morsica G; Bagaglio S; Cernuschi M; Bigoloni A; Uberti-Foppa C; Lazzarin A; Hasson H
    New Microbiol; 2016 Apr; 39(2):110-3. PubMed ID: 27196548
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Liver fibrosis progression and clinical outcomes are intertwined: role of CD4+ T-cell count and NRTI exposure from a large cohort of HIV/HCV-coinfected patients with detectable HCV-RNA: A MASTER cohort study.
    Focà E; Fabbiani M; Prosperi M; Quiros Roldan E; Castelli F; Maggiolo F; Di Filippo E; Di Giambenedetto S; Gagliardini R; Saracino A; Di Pietro M; Gori A; Sighinolfi L; Pan A; Postorino MC; Torti C;
    Medicine (Baltimore); 2016 Jul; 95(29):e4091. PubMed ID: 27442636
    [TBL] [Abstract][Full Text] [Related]  

  • 25. There is no difference in hepatic fibrosis rates of patients infected with hepatitis C virus and those co-infected with HIV.
    Souza AR; Tovo CV; Mattos AA; Chaves S
    Braz J Med Biol Res; 2008 Mar; 41(3):223-8. PubMed ID: 18176724
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Highly active antiretroviral therapy-related hepatotoxicity in human immunodeficiency virus and hepatitis C virus co-infected patients with advanced liver fibrosis in Taiwan.
    Chou CC; Tsai HC; Wu KS; Sy CL; Chen JK; Chen YS; Lee SS
    J Microbiol Immunol Infect; 2016 Aug; 49(4):546-53. PubMed ID: 25440980
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of hepatic fibrosis in HIV/HCV co-infected individuals in Yaoundé, Cameroon: usefulness of APRI score in resource-constrained settings.
    Dobseu R; Nanfack A; Kowo M; Ambada G; Kamgaing R; Chenwi C; Fainguem N; Ka'e A; Ngangoum E; Sosso S; Tchiegang C; Ndjolo A
    BMC Infect Dis; 2020 Oct; 20(1):758. PubMed ID: 33059627
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessing mortality in women with hepatitis C virus and HIV using indirect markers of fibrosis.
    Bambha K; Pierce C; Cox C; French AL; Tien PC; Sharp GB; Augenbraun M; Glesby MJ; Villacres MC; Plankey M; Strickler HD; Gange SJ; Peters MG
    AIDS; 2012 Mar; 26(5):599-607. PubMed ID: 22156972
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Non-invasive assessment of liver steatosis and fibrosis in HIV/HCV- and HCV- infected patients.
    Li Vecchi V; Giannitrapani L; Di Carlo P; Mazzola G; Colletti P; La Spada E; Vizzini G; Montalto G; Soresi M
    Ann Hepatol; 2013; 12(5):740-8. PubMed ID: 24018492
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Non-invasive fibrosis biomarkers - APRI and Forns - are associated with liver stiffness in HIV-monoinfected patients receiving antiretroviral drugs.
    Hasson H; Merli M; Galli L; Gallotta G; Carbone A; Messina E; Bagaglio S; Morsica G; Salpietro S; Castagna A; Lazzarin A; Uberti-Foppa C
    Liver Int; 2013 Aug; 33(7):1113-20. PubMed ID: 23534616
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Evaluation of APRI score in liver disease following the introduction of antiretroviral therapy in HIV and HCV coinfected versus HIV monoinfected patients].
    Antonello VS; Tovo CV; Kliemann DA; Santos BR; Zaltron VF
    Rev Soc Bras Med Trop; 2010; 43(6):678-81. PubMed ID: 21181022
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prediction of liver stiffness by serum indexes in HCV-infected patients with or without HIV coinfection.
    Merchante N; Mena Á; Pascasio JM; Marco A; Rodriguez M; Hernandez-Guerra M; Simón MA
    Medicine (Baltimore); 2021 Nov; 100(46):e27838. PubMed ID: 34797315
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cocaine/crack use is not associated with fibrosis progression measured by AST-to-Platelet Ratio Index in HIV-HCV co-infected patients: a cohort study.
    Martel-Laferrière V; Nitulescu R; Cox J; Cooper C; Tyndall M; Rouleau D; Walmsley S; Wong L; Klein MB;
    BMC Infect Dis; 2017 Jan; 17(1):80. PubMed ID: 28095797
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepatic steatosis progresses faster in HIV mono-infected than HIV/HCV co-infected patients and is associated with liver fibrosis.
    Pembroke T; Deschenes M; Lebouché B; Benmassaoud A; Sewitch M; Ghali P; Wong P; Halme A; Vuille-Lessard E; Pexos C; Klein MB; Sebastiani G
    J Hepatol; 2017 Oct; 67(4):801-808. PubMed ID: 28527666
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Time on antiretroviral therapy is a protective factor for liver fibrosis in HIV and hepatitis C virus (HCV) co-infected patients.
    Tural C; Fuster D; Tor J; Ojanguren I; Sirera G; Ballesteros A; Lasanta JA; Planas R; Rey-Joly C; Clotet B
    J Viral Hepat; 2003 Mar; 10(2):118-25. PubMed ID: 12614468
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Comprehensive Analysis of the Impact of HIV on HCV Immune Responses and Its Association with Liver Disease Progression in a Unique Plasma Donor Cohort.
    Zhang YH; Zhao Y; Rajapaksa US; Lawrence TM; Peng YC; Liu J; Xu K; Hu K; Qin L; Liu N; Sun H; Yan HP; Repapi E; Rowland-Jones S; Thimme R; McKeating JA; Dong T
    PLoS One; 2016; 11(7):e0158037. PubMed ID: 27455208
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Management of hepatitis C virus infection in HIV/HCV co-infected patients: clinical review.
    Singal AK; Anand BS
    World J Gastroenterol; 2009 Aug; 15(30):3713-24. PubMed ID: 19673011
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection.
    Aranzabal L; Casado JL; Moya J; Quereda C; Diz S; Moreno A; Moreno L; Antela A; Perez-Elias MJ; Dronda F; Marín A; Hernandez-Ranz F; Moreno A; Moreno S
    Clin Infect Dis; 2005 Feb; 40(4):588-93. PubMed ID: 15712082
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Liver toxicity and risk of discontinuation in HIV/hepatitis C virus-coinfected patients receiving an etravirine-containing antiretroviral regimen: influence of liver fibrosis.
    Casado JL; Mena A; Bañón S; Castro A; Quereda C; Moreno A; Pedreira J; Moreno S
    HIV Med; 2016 Jan; 17(1):62-7. PubMed ID: 26122981
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HIV-HCV co-infected patients with low CD4+ cell nadirs are at risk for faster fibrosis progression and portal hypertension.
    Reiberger T; Ferlitsch A; Sieghart W; Kreil A; Breitenecker F; Rieger A; Schmied B; Gangl A; Peck-Radosavljevic M
    J Viral Hepat; 2010 Jun; 17(6):400-9. PubMed ID: 19780945
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.